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Inﬂammation contributes to leukocyte migration, termed insulitis, and β-cell loss in type 1 diabetes (T1D). Naturally occurring
anthraquinones are claimed as anti-inﬂammatory compounds; however, their actions are not clear. This study aimed to investigate
the eﬀect and mechanism of catenarin on the inﬂammatory disease, T1D. Catenarin and/or its anthraquinone analogs dose-
dependently suppressed C-X-C chemokine receptor type 4 (CXCR4)- and C-C chemokine receptor type 5 (CCR5)-implicated
chemotaxis in leukocytes. Catenarin, the most potent anthraquinone tested in the study, prevented T1D in nonobese diabetic
mice. Mechanistic study showed that catenarin did not act on the expression of CCR5 and CXCR4. On the contrary, catenarin
inhibited CCR5- and CXCR4-mediated chemotaxis via the reduction of the phosphorylation of mitogen-activated protein kinases
(p38 and JNK) and their upstream kinases (MKK6 and MKK7), and calcium mobilization. Overall, the data demonstrate the
preventive eﬀect and molecular mechanism of action of catenarin on T1D, suggesting its novel use as a prophylactic agent in T1D.
1.Introduction
T1D is a life-threatening disease arising from the destruction
of insulin-producing β cells by leukocytes with a strong
inﬂammatory reaction. Five to 30% of diabetic patients are
diagnosed with T1D. Patients with T1D share many similar
genetic and immunopathological features with nonobese
diabetic (NOD) mice, an established mouse model for T1D
study [1, 2]. During T1D development, leukocytes begin to
invade the pancreatic islets of NOD mice [3]. T lymphocytes
are main players in T1D though other leukocytes such as
B lymphocytes, dendritic cells, macrophages, and NK cells
are also implicated [4, 5]. Leukocyte inﬁltration into the
pancreatic islets, called insulitis, contributes to a gradual loss
of pancreatic β cells, leading to insulin insuﬃciency and
deﬁciency, a hallmark of T1D [6]. This inﬁltration is thought
to be regulated by chemokine receptors and chemokines
[7–10].
Inﬂammation involves activation and directed migration
of leukocytes from the venous system to the inﬂamed sites
where chemokines are produced and released. Nonresolved
inﬂammation is associated with a broad category of dis-
eases, that is, autoimmune diseases, cancers, and so forth
[11]. In recent years, molecular studies have identiﬁed a2 Evidence-Based Complementary and Alternative Medicine
variety of proteins and chemical mediators implicated in
inﬂammation. Among them, chemokines and their cognate
receptorsplayanessentialroleininﬂammatoryresponseand
therefore, could be potential drug targets for inﬂammatory
diseases [12–15]. T cells are thought to be important
players in T1D [16], although other leukocytes are also
involved in the disease [4]. CXCR4 is expressed in na¨ ıve T
cells and the other leukocytes [17]. CCR5 is preferentially
expressed in activated T cells and macrophages [18–20].
Therefore, interference with CXCR4 and CCR5 could be a
promising approach for insulitis and T1D prophylaxis and
therapy. Chemokine receptors belong to a family of 7-helix
transmembrane G-protein-coupled receptors (GPCRs). On
chemokine engagement, chemokine receptors initiate the
binding of Gα subunit to guanosine triphosphate and the
dissociation of Gα subunit from Gβγ subunit. This activates
protein tyrosine kinases, mitogen-activated protein kinases
(MAPKs), and phospholipase C. Secondary messengers,
inositol triphospahte and diacylglycerol, which are converted
from phosphatidylinositol by phospholipase C, increase
calcium mobilization and activation of protein kinase C,
respectively. The above biochemical event results in cell
chemotaxis and other cell functions [21].
Inﬂammation is involved in insulitis and β cell destruc-
tion in T1D [6]. Thus, a couple of therapeutic agents such
as cyclooxygenase-2 (Cox-2) inhibitors, acetylsalicylic acid
and tenidap and immune modulators, FK506, lisofylline and
cytopiloyne, were reported to prevent T1D by inhibiting a
variety of inﬂammatory pathways in immune cells [22–25].
However, their antidiabetic eﬃcacy has been unsatisfactory.
Therefore, search for novel anti-inﬂammatory agent for T1D
therapy is practically signiﬁcant. Medicinal plants, used in
complementary and alternative medicine worldwide, are a
rich source of anti-inﬂammatory compounds [26]. More-
over, a recent review on traditional Chinese medicines sug-
gests that Chinese herbal formulations with hypoglycemic
andanti-inﬂammatoryactivitiesareusefultoinhibitdiabetes
development [27]. Therefore, anti-inﬂammatory comple-
mentary and alternative medicine may be beneﬁcial for
T1D. Catenarin, cascarin, emodin, and rhein represent a
class of naturally occurring anthraquinone compounds from
medicinal herbs. Most of them are best known as active
compounds found in laxative herbs, commonly used to
treat constipation. Apart from the laxative activity, emodin,
the most studied anthraquinone in the literature, was
claimed to possess anti-inﬂammatory activity as well as
anticancer, antimicrobial, diuretic, vasorelaxing and phytoe-
strogen activities [3, 28–31]. Emodin was shown to inhibit
hepatitis[30],pancreatitis[32],andNF-κBactivation[33]in
cells and animals, suggesting its anti-inﬂammatory property.
Another anthraquinone, rhein, is an active metabolite of
diacerhein, a commercial drug used for osteoarthritis [34].
These publications suggest that anthraquinone compounds
may have anti-inﬂammatory activity. Nevertheless, the anti-
inﬂammatory eﬀect and mechanism of the anthraquinones
on T1D and other inﬂammatory diseases are poorly under-
stood.
In this study, we examined the eﬀect of catenarin and
its derivatives on CCR5- and CXCR4-implicated chemotaxis
in T cells. We then evaluated the in vivo eﬀect of catenarin
on leukocyte migration during T1D in NOD mice. Finally,
we investigated the likely mechanism by which catenarin
inhibited chemotaxis in T cells.
2.MaterialsandMethods
2.1. Drug Administration, Diabetes Measurement, Immuno-
histochemistry, and Cellularity Analysis. NOD mice were
maintained according to the institutional animal care and
utilization committee (OMiIBAYW20100043). Female NOD
mice were intraperitoneally injected with a dose of catenarin
(4, 20 and 40mg/kg body weight (BW)), acetylsalicylic acid
(40mg/kg), or vehicle (0.1% dimethyl sulfoxide (DMSO),
negative control) three times per week, from 4 to 30 weeks of
age. As previously published [24], glycosuria and glycemia in
the above mice were monitored every week using a Clinistix
strip (Bayer, Pittsburgh, PA, USA) and an Elite glucometer
(Bayer), respectively. Animals are considered diabetic when
blood glucose levels were >250mg/dL for 2 consecutive
weeks. The percentage of glycosylated hemoglobulin A1C
(HbA1C) in blood samples was measured using a DCA 2000
analyzer (Bayer). Part of the pancreata from the NOD mice
wassnap-frozenandstainedwithanti-insulinandanti-CD45
antibodies (Abs) as published [24]. For cellularity analysis,
the islets from the rest of the pancreata were smashed,
counted and stained with the antibodies against leukocyte
markers, and underwent FACS analysis.
2.2.TranswellMigrationAssay. JK-EF1α-CCR5cells,aJurkat
clone stably transduced by a lentiviral vector harbouring a
CCR5 gene under the control of EF1α promoter [35], Jurkat
cells (ATCC No. TIB-152), and splenocytes from 7-week-
old NOD mice were used to measure CXCR4- and CCR5-
mediated chemotaxis as previously described [35]. Brieﬂy,
the cells, which were pretreated with vehicle (0.1% DMSO),
catenarin, and/or its derivatives for 1h, were subjected to
transwell migration assays with or without chemokine for
an additional 4h. The migrated cells were quantiﬁed using
hematocytometry. The migration index (MI) was obtained
from the formula: MI = 100 × (number of anthraquinone-
treated cells migrating toward the chemokine and num-
ber of anthraquinone-treated cells migrating toward the
medium)/(number of vehicle-treated cells migrating toward
thechemokineandnumberofvehicle-treatedcellsmigrating
toward the medium). To evaluate the eﬀect of catenarin on
the chemotaxis-mediated by MKK6 and MKK7, Jurkat cells
were transiently electroporated with pcDNA3-HA-MKK6EE
[36] or pMEV2HA-MKK7EE (Biomyx Technology, CA,
USA). Total lysates underwent immunoblot with anti-
MKK6, anti-MKK7, and anti-p85 Abs.
2.3. μ-Slide Migration Assay [37]. The μ-slide migration
assay was analyzed according to the manufacturer’s instruc-
tions (IBIDI GmbH, Germany). Brieﬂy, Jurkat cells were
loaded in the μ-slide, which was precoated with ﬁbronectin.
Time-lapsevideomicroscopywasusedtorecordtheposition
of cells at 5-min intervals. Images of cell movement toEvidence-Based Complementary and Alternative Medicine 3
the chemokine (0.5μg / m L )o rv e h i c l e( 0 . 1 %D M S O )w e r e
assessed by the ImageJ plugin software for analysis of track
data.
2.4. Detection of Intracellular Calcium. Ten million JK-
EF1α-CCR5 cells and Jurkat cells were pretreated with
vehicle (0.1% DMSO), catenarin (1μg/mL), SB202190 (a
p38 inhibitor, 3.3μg/mL), or SP600125 (a JNK inhibitor,
2.2μg/mL) for 1h. After washing, the cells were preloaded
with Fura 2-AM (5μM) in modiﬁed Krebs-Henseleit buﬀer
(1.3mM CaCl2,2 0m MH e p e s ,1 5m Mg l u c o s e ,a n d2 %B S A
at pH7.4) for 30min at 25◦C for 1h. After extensive washing,
the cells were stimulated with a dose (100ng/mL) of MIP-
1β or SDF-1β. Intracellular calcium was measured using
a ﬂuorescence spectrophotometer (CAF 110, Jasco, Tokyo,
Japan) at the excitation wavelengths of 340 and 380nm and
emission wavelength of 500nm. The ratio of ﬂuorescence
intensity at 340nm to that at 380nm represents the level of
intracellular calcium.
2.5. FACS Analysis. JK-EF1α-CCR5 cells and Jurkat cells,
which had already been pretreated with vehicle (0.1%
DMSO) or catenarin (1μg/mL) for 1h, were stained with
isotype Ab, FITC-conjugated anti-CCR5 Ab, or anti-CXCR4
Ab plus FITC-conjugated secondary Ab. The cells were
subjected to FACS analysis and results were analyzed using
FCS Express software. Pancreatic islets were smashed and
islet cells were collected. The cells were stained with anti-
CCR5 Ab or anti-CXCR4 Ab and underwent FACS analysis.
2.6. Immunoblot. JK-EF1α-CCR5 cells and Jurkat cells,
which had already been pretreated with vehicle (0.1%
DMSO) or catenarin (1μg/mL) for 1h, were stimulated with
MIP-1β or SDF-1β for 0, 5, 10, and 15min. Total lysates
from the cells were subjected to SDS-PAGE and blotted
with Abs against the MAPKs or their phosphorylated forms.
Proteins were visualized using ECL kits and detected using
ChemiGenius image analysis system (Syngene, Cambridge,
UK). The relative intensities of the protein bands were
quantitated using Syngene GeneTools software.
2.7. Statistical Analysis. Data from three or more indepen-
dent experiments are presented as mean ± standard error
(SE). ANOVA and Mann-Whitney U Test were used for
statistical analysis between control and treatment groups in
in vitro and in vivo studies, respectively.
2.8. Reagents and Cells. Catenarin was purchased from
ChromaDex(CA,USA).DMSO,acetylsalicylicacid,emodin,
physcion, rhein, resveratrol, and secondary Abs against
mouse and rabbit sera were purchased from Sigma (MO,
USA). WST-1 assay was purchased from Roche (IN,
USA). Human chemokines (SDF-1β and MIP-1β), mouse
chemokines (SDF-1α and MIP-1β), FITC-conjugated anti-
CCR5 Ab, anti-CXCR4 Ab, isotype Ab, and FITC-conjugated
secondary Ab were purchased from R&D Systems (Min-
neapolis, MN, USA), and anti-insulin Ab and anti-p85 were
from Santa Cruz (CA, USA). Antibodies against MAPKs,
MKK6/7 and their phosphorylated proteins were purchased
from Cell Signaling (MA, USA), and anti-CD45, anti-CD4,
anti-CD8, anti-CD11c, anti-B220, anti-CD68, and anti-
CD49 Abs were from BD Biosciences (CA, USA). PVDF
membrane and enhanced chemoluminescence detection
reagent were purchased from GE healthcare (Piscataway, NJ,
USA),andFura2-AMwasfromMolecularProbe(OR,USA).
3. Results
3.1. Catenarin Inhibits CCR5- and CXCR4-Mediated Chemo-
taxis in Jurkat Cells and Splenocytes. Leukocyte migration
(insulitis) is associated with β-cell loss in T1D [6]a n d
mediated by chemokines and their receptors [37]. In this
study, we ﬁrst evaluated the medicinal eﬀect of catenarin
and its 3 derivatives (Figure 1(a)) on chemokine-directed
chemotaxis in Jurkat cells and their stable clone, JK-EF1α-
CCR5 cells, using transwell migration assays. CXCR4 and
CCR5 chemokines were selected here because both are
expressed in na¨ ıve and activated T cells, a dominant type
of leukocytes in eliciting T1D. The half maximal inhibitory
concentration (IC50) of catenarin, emodin, cascarin, and
rhein on chemotaxis, triggered by CCR5 ligand, MIP-1β,
in JK-EF1α-CCR5 cells was 0.24, 0.36, 0.39, and 3.1μg/mL,
respectively (Figure 1(b)). In contrast, the IC50 of catenarin,
emodin, cascarin and rhein on chemotaxis, triggered by
CXCR4 ligand, SDF-1β, in Jurkat cells was 0.46, 1.8,
0.86, and 2.8μg/mL, respectively (Figure 1(c)). Of note,
catenarin, the most potent anthraquinone tested in this
study, inhibited CCR5- and CXCR4-implicated chemotaxis
in a dose-dependent manner (Figure 1). In contrast, two
anti-inﬂammatory compounds, resveratrol and acetylsali-
cylic acid, had no signiﬁcant antichemotactic activity in
Jurkat cells (Figures 1(b) and 1(c)). Moreover, the viability
of JK-EF1α-CCR5 cells and Jurkat cells exposed to the
anthraquinones at a dose of 0 to 2.5μg/mL for 1h is
>80% based on WST-1 assays (Figure 1(d) and data not
shown). These data suggest that the suppression of CCR5-
and CXCR4-implicated chemotaxis by the anthraquinones
is not due to cytotoxicity. We also examined the eﬀect of
c a t e n a r i no nM I P - 1 β and SDF-1α-mediated chemotaxis in
NOD splenocytes. The data showed that catenarin signiﬁ-
cantly inhibited CXCR4- and CCR5-mediated chemotaxis in
splenocytes (Figure 1(e)) in a similar way as it did in Jurkat
cells (Figures 1(b) and 1(c)).
We further used μ-slide migration assays to record the
directional track of Jurkat cells moving toward chemokines
[38]. Track plot data showed that vehicle-treated Jurkat cells
andJK-EF1α-CCR5cellsmigratedtowardstheleftsideofthe
μ-slide where SDF-1β and MIP-1β were loaded, respectively
(upper row, Figure 1(f)). Strikingly, catenarin treatment
abolished the movement of Jurkat cells and JK-EF1α-CCR5
cells toward SDF-1β and MIP-1β (lower row, Figure 1(f)).
We, for the ﬁrst time, demonstrate that catenarin and its
analogs could inhibit CXCR4- and CCR5-implicated cell
migration as shown by the two types of migration assays.
The data suggest that catenarin eﬀectively inhibits leukocyte
chemotaxis.4 Evidence-Based Complementary and Alternative Medicine
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Figure 1:Eﬀectofanthraquinonesonchemotaxisandcellviability(a).Chemicalstructureof4anthraquinones:catenarin,emodin,cascarin
and rhein (b) and (c). JK-EF1α-CCR5 (b) and Jurkat cells (c) were incubated with the indicated doses (0–2.5μg/mL) of catenarin (),
emodin (•), cascarin (), rhein (), acetylsalicylic acid (x) or resveratrol (), a negative control, for 1h. The cells were subjected to
chemotaxis assays in the presence or absence of MIP-1β (100ng/mL) (b) and SDF-1β (100ng/mL) (c) for 4h. The migration index (MI)
is presented as percentage (%). Data from 3 independent experiments are expressed as mean ± SE. P (∗) < 0.05 (d). JK-EF1α-CCR5 cells
(105 per well) were pretreated with the indicated doses (0–2.5μg/mL) of resveratrol, acetylsalicylic acid, or the anthraquinones for 1h; and
cell viability was analyzed by WST-1 assay. Data from 3 independent experiments are presented as means ± SE. E. NOD splenocytes were
preincubated with catenarin (1μg/mL) or vehicle for 1h. The cells underwent chemotaxis in the presence or absence of MIP-1α (100ng/mL)
and SDF-1β (100ng/mL). Migration index (MI) was measured. Data from 3 independent experiments are expressed as mean ± SE. P (∗)
< 0.05. (f). Track plots showing the directional migration of Jurkat cells (left column) and JK-EF1α-CCR5 (right column) and, which were
pretreated with vehicle (upper row) or catenarin (0.5μg/mL, lower row), toward SDF-1β (50ng/mL, left column) or MIP-1β (50ng/mL,
right column) in μ-slide migration assays. Each started in the center of the diagram with SDF-1β or MIP-1β on left side. Cells were tracked
for 8h. Tracks of cells moving toward and away from the chemokines are highlighted in black and red, respectively.
3.2. Catenarin Suppresses Leukocyte Migration, Islet Destruc-
tion, and T1D in NOD Mice. We turned to investigate
the in vivo eﬀect of catenarin on T1D, an inﬂammatory
disease caused by the destruction of pancreatic β cells by
leukocytes, in NOD mice. We ﬁrst examined the cumulative
incidence of diabetes in NOD mice treated with or without
catenarin for 30 weeks. All NOD mice (100%) treated
with vehicle spontaneously developed T1D from the age
of 24 weeks (Figure 2(a)). In contrast, 83% of 30-week-
old NOD mice treated with the anti-inﬂammatory drug,
acetylsalicylic acid [25], developed T1D (Figure 2(a)). Of
note, catenarin at 0.4, 4, and 20mg/kg reduced diabetes in
the age-matched mice by 33%, 86%, and 100%, respectively
(Figure 2(a)).ThedatashowedthatcatenarinpreventedT1D
in NOD mice to a greater extent than acetylsalicylic acid,
a Cox-2 inhibitor. Next, we checked islet architecture and
leukocyte migration in the pancreata of these mice (Figure
2(b)). Severe islet destruction and leukocyte inﬁltration was
found in the pancreata of NOD mice treated with vehicle,
0.4mg/kg catenarin and acetylsalicylic acid (Figure 2(b)).
In marked contrast, a marginal-to-modest islet destruction
and leukocyte inﬁltration were found in the pancreatic islets6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀect of catenarin on prevention of diabetes in NOD mice. (A) The cumulative diabetic incidence, from 3 to 30 weeks of age, was
monitored in female NOD mice treated with vehicle (control), catenarin (0.4, 4, and 20mg/kg) or acetylsalicylic acid (ASA, 40mg/kg), 3
times per week, from 4 to 30 weeks. The number of mice per group is indicated in the parentheses. (B) Histological images of the pancreata
of NOD mice. The pancreata of 30-week-old NOD mice (a)–(e) and diabetes-free 5-week-old NOD mice (f) were ﬁxed and double-stained
with anti-insulin (β cells, brown) and anti-CD45 (leukocytes, purple) Abs. Scale bar, 100μm. (C) and (D) The blood glucose level (C) and
HbA1C percentage (D) of the above-mentioned mice at the age of 4 weeks (before treatment) and 30 weeks were measured. (E), (F), and
(G). The number of total cells and leukocyte subsets of pancreatic islets (E) from NOD mice (A) was determined. Anti-CD4 (CD4+ Tc e l l s ) ,
anti-CD8 (CD8+ T cells), anti-CD11c (DCs, dendritic cells), anti-B220 (B cells), anti-CD68 (macrophages), and anti-CD49 (NK cells) Abs
were used to determine leukocyte subsets.
of NOD mice treated with catenarin at 4mg/kg and over
(Figure 2(b)). These histopathological data supported that
catenarin could strongly maintain the islet integrity and
suppress the leukocyte migration in 30-week-old NOD mice.
T h el e v e l so fb l o o dg l u c o s ea n dH b A1C represent short-
term and long-term glycemic control in diabetic mice. We
found that 4-week-old NOD mice had a normal level of
blood glucose and HbA1C (Figures 2(c) and 2(d)). However,
30-week-old NOD mice treated with vehicle, 0.4mg/kg
catenarin and acetylsalicylic acid had an elevated level of
bloodglucoseandHbA1C (Figures2(c)and2(d)).Incontrast,
NOD mice treated with catenarin at 4mg/kg and overEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Eﬀect of catenarin on calcium mobilization elicited by MIP-1β or SDF-1β. Ten million JK-EF1α-CCR5 cells (a) and Jurkat cells
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eﬀectively reduced the level of blood glucose and HbA1C
(Figures 2(c) and 2(d)). Our data demonstrate that the
maintenance of blood glucose by catenarin is consistent with
the islet integrity.
Catenarin suppressed leukocyte inﬁltration into the
pancreas in the late-stage diabetes (30-week-old mice)
(Figure 2(b)). Similarly, it reduced leukocyte inﬁltration and
the severity of insulitis in the early-stage diabetes (12-week-
old NOD mice) (data not shown). The data suggest that
catenarin inhibits the leukocyte migration into pancreas
during T1D development.
We further analyzed the number and type of leukocytes
in pancreatic islets of 30-week-old NOD mice using FACS
analysis. In agreement with the eﬀect of catenarin on
leukocyte inﬁltration as shown in histopathological data
(Figure 2(b)), catenarin signiﬁcantly reduced the number8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Eﬀect of catenarin on MAPK phosphorylation elicited by MIP-1β or SDF-1β. One million JK-EF1α-CCR5 cells (a) and Jurkat
cells (b) were pretreated with vehicle or catenarin (1μg/mL) for 0, 5, 10, and 15min, followed by the addition of (a) MIP-1β (100ng/mL)
or (b) SDF-1β (100ng/mL). Total lysates were immunoblotted with the Abs against MAPKs (p38, JNK, and ERK) or their phosphorylated
proteins. Representative data and the ratio of the signal of the phosphorylated MAPKs to that of total MAPKs are shown.
of total leukocytes, CD4+ T cells, macrophages, and B
cells in the pancreatic islets of NOD mice in a dose-
dependent fashion (Figure 2(e)). Catenarin also reduced
the number of CD8+ T cells and dendritic cells although
this decrease was not statistically signiﬁcant (Figure 2(e)).
However, acetylsalicylic acid had no signiﬁcant decrease in
thenumberofleukocytesandtheirsubsets(Figure 2(e)).The
dataconcludethatcatenarininhibitstheleukocytemigration
to pancreatic islets of NOD mice (Figure 2) in a similar way
as it inhibits the chemotaxis of Jurkat T cells and splenocytes
(Figure 1).
Overall, the data demonstrate that catenarin prevents the
leukocyte migration into the pancreas (i.e., insulitis) and,
consequently, reduces islet destruction and T1D in NOD
mice. Besides, catenarin is more eﬀective than acetylsalicylic
acid in T1D prevention.
3.3. Catenarin Does Not Aﬀect Surface Expression of CCR5
andCXCR4Receptors. Reductionofchemotaxisbycatenarin
may be due to a decrease in cell surface expression of
CCR5 and CXCR4 receptors due to the internalization of
these receptors induced by catenarin. To test this possi-
bility, catenarin was used to treat JK-EF1α-CCR5 cells or
Jurkat cells. After treatment for 1h, the surface expres-
sion level of CCR5 on JK-EF1α-CCR5 cells and CXCR4
on Jurkat cells was measured using FACS analysis. No
diﬀerence was observed in the expression of CCR5 and
CXCR4 on the cell surface (Figure 3), thus ruling out theEvidence-Based Complementary and Alternative Medicine 9
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Figure 6: Eﬀect of catenarin on MKK6 and MKK7 phosphorylation elicited by MIP-1β or SDF-1β. JK-EF1α-CCR5 cells (a) and Jurkat
cells (b) received the same treatment as described in Figure 5. Abs against MKK6, MKK7, and their phosphorylated proteins were used in
immunoblot.
possibility that catenarin works at the level of the chemokine
receptors.
3.4. Catenarin Inhibits Calcium Mobilization in CCR5 and
CXCR4 Pathways. Calcium is known to be a secondary
messenger downstream of some chemokine receptors in
T cells [21]. Thus, we examined the eﬀect of catenarin,
SB202190 (a p38 inhibitor) and SP600125 (a JNK inhibitor)
on calcium mobilization triggered by MIP-1β or SDF-1β.
Interestingly, catenarin dramatically reduced calcium inﬂux
triggered by both chemokines in a dose-dependent manner
(Figure 4). The p38 inhibitor and JNK inhibitor signiﬁcantly
diminished MIP-1β-a n dS D F - 1 β-elicited calcium inﬂux in
JK-EF1α-CCR5 and Jurkat cells, respectively (Figure 4). The
above data imply that the inhibition of CCR5- or CXCR4-
mediated chemotaxis by catenarin involves calcium and the
MAPKs, p38, and JNK.
3.5. Catenarin Inhibits the Activation of MAPK Cascades
in CCR5 and CXCR4 Pathways. MAPKs are known to
function the downstream of chemokine receptors [21].
Therefore, we checked the eﬀect of catenarin on MAPK
family, p38, JNK, and ERK1/2, in the CCR5 and CXCR4
pathways. We found that catenarin at 1μg/mL inhibited the
phosphorylation of the p38 and JNK in JK-EF1α-CCR5 and
Jurkat cells in response to MIP-1β (Figure 5(a))a n dS D F -
1β (Figure 5(b)). However, catenarin slightly increased in
the phosphorylation of ERK1/2 (Figure 5). The data suggest
that the antichemotactic eﬀect of catenarin is consistent with
the inhibition of p38 and JNK by catenarin, but not the
activation of ERK1/2 by catenarin.
MAPKs can be activated by their upstream regulators,
the MAPK kinases (MKKs). MKK3 and MKK6 regulate
the activation of p38, whilst MKK4 and MKK7 regulate
the activation of JNK [39, 40]. We further examined
the eﬀect of catenarin on the activation of MKK6 and
MKK7. Catenarin signiﬁcantly reduced the phosphorylation
of MKK6 in K-EF1α-CCR5 cells triggered by MIP-1β and
Jurkat cells triggered by SDF-1β (upper panels, Figures
6(a) and 6(b)). Similarly, catenarin signiﬁcantly decreased
the phosphorylation of MKK7 by either chemokines (lower
panels, Figures 6(a) and 6(b)). These data conﬁrm that
catenarin inhibits MAPKs, p38 and JNK, and their upstream
regulators, MKK6 and MKK7.
To further prove that catenarin inhibited chemotaxis via
the signaling cascade of MKKs and MAPKs, we tested the
eﬀect of catenarin in Jurkat cells, which were transfected
with an active mutant of MKK6 or MKK7. Accordingly,
catenarin signiﬁcantly abolished Jurkat cell migration medi-
ated by MKK6 and MKK7 (Figure 7(a)). Similar results were10 Evidence-Based Complementary and Alternative Medicine
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Figure 7: Eﬀect of catenarin on MKK6- or MKK7-mediated migration (a). Jurkat cells were electroporated with pcDNA3-HA-MKK6EE
or pMEV2HA-MKK7EE. The cells underwent chemotaxis assay, and the migration index (MI) was determined (upper panel). Data from 3
independentexperimentsareexpressedasmean ±SE.P (∗)<0.05.TheexpressionlevelofMKK6EE,MKK7EE,andp85,aninternalcontrol,
was determined by immunoblot using anti-MKK6, anti-MKK7, and anti-p85 Abs (lower panel) (b). Scheme describing the molecular
mechanism by which catenarin inhibits leukocyte migration and, thus insulitis in NOD mice. Catenarin inhibits leukocyte migration
mediated by CCR5 and CXCR4 via the inactivation of MAPKs (p38 and JNK), MKKs (MKK6 and MKK7), and calcium mobilization.Evidence-Based Complementary and Alternative Medicine 11
observed in primary CD4+ T cells with the overexpression of
MKK6 or MKK7 (data not shown). Overall, these data sug-
gest that catenarin inhibits CCR5- and CXCR4-implicated
chemotaxis via the inactivation of the MKK/MAPK pathway
and calcium inﬂux (Figure 7(b)).
4. Discussion and Conclusions
In this study, we investigated the anti-inﬂammatory eﬀect
and mechanism of catenarin and/or its analogs using
human Jurkat cells, mouse splenocytes, and NOD mice. We
demonstrate that catenarin, the most potent anthraquinone
tested in our study, strongly suppresses leukocyte migration
in the diabetes. Moreover, mechanistic studies showed
that catenarin, as well as probably its analogs, acts by
targeting the MKK/MAPK signaling cascades and calcium
downstream of CCR5 and CXCR4 receptors, expressed in
leukocytes.
Naturally occurring anthraquinone compounds are
claimed to have a variety of bioactivities. A majority of
the literature demonstrate the action of the anthraquinones
for constipation [41–43] and cancers [3, 28, 44]. However,
their role in inﬂammation is poorly studied. Here, CXCR4-
and CCR5-implicated chemotaxis in Jurkat T cells was
employed as an in vitro system to investigate the anti-
inﬂammatory eﬀect and action of the anthraquinones. With
this system, we showed the antichemotactic eﬀect (Figure 1)
and mechanism of catenarin and its anthraquinone analogs
in T cells (Figures 3–7). In sharp contrast, two anti-
inﬂammatory compounds, resveratrol [45] and acetylsal-
icylic acid [25] could not inhibit chemotaxis (Figures
1 and 2). Clearly, not all anti-inﬂammatory compounds
can eﬀectively suppress leukocyte chemotaxis, suggesting
the unique anti-chemotactic feature of catenarin and its
analogs in leukocytes (Figure 1). Inhibition of chemotaxis
in leukocytes by catenarin was further conﬁrmed by the
reduction of insulitis and diabetes in NOD mice (Figure 2
and data not shown). The anti-inﬂammatory action of
catenarininthisstudyisconsistentwiththeﬁndingsshowing
that emodin, the most extensively studied anthraquinone,
inhibited hepatitis [30], pancreatitis [32], and NF-κB[ 33]
in diﬀerent model systems. In addition, diacerhein, a drug
used for osteoarthritis that has an anthraquinone structure
[34], showed beneﬁcial eﬀects on T1D in NOD mice [46].
The data suggest that catenarin and its anthraquinone
analogs are prophylactically useful for T1D and, probably,
other inﬂammatory disorders. Of note, catenarin has higher
antichemotactic activity than emodin, cascarin, and rhein.
Interestingly, this activity seems to be related to the num-
ber of hydroxyl group at R2 and R3 in anthraquinones
(Figure 1).
Chemokines and their receptors are potential drug tar-
getsininﬂammatorydiseasessuchasT1D[14,47].CXCR4is
broadly expressed in all the leukocytes and CXCR5 is ex-
pressed in macrophages and activated T cells, a pivotal play-
erinautoimmunedestructionofpancreaticβ cells[17].Both
receptors are known to regulate T1D, although their protec-
tive roles in T1D are controversial [7, 18, 19, 48]. In view
of the importance of CCR5 and CXCR4 in T1D, in this
study we explored the anti-inﬂammatory eﬀect of catenarin
based on CCR5- and CXCR4-implicated migration assays.
Surprisingly, catenarin and its analogs dose-dependently in-
hibited CCR5- and CXCR4-mediated chemotaxis in JK-
EF1α-CCR5 and Jurkat cells, respectively (Figure 1). This
inhibition in human Jurkat T cells was further conﬁrmed in
mouse splenocytes and NOD mice (Figures 1 and 2). The
data also suggest that the antichemotactic eﬀect of catenarin
and its analogs is not limited to T cells and exists in other
leukocytes.
All chemokine receptors belong to the G-protein-
coupled receptor family. Upon chemokine binding, the
receptor induces Gα activation and leads to a signaling
cascade that comprises activation of tyrosine kinases, ser-
ine/threonine kinases, and phospholipases, and an increase
in secondary messengers (calcium, diacylglycerol, and phos-
phatidylinositol) [21, 49]. In this study, catenarin failed to
aﬀect the surface expression level of CCR5 and CXCR4,
suggesting that catenarin does not target the receptors
themselves (Figure 3). However, catenarin suppressed the
activation of chemokine-receptor downstream mediators,
MKK6/p38 and MKK7/JNK, and calcium mobilization
(Figures 4, 5, and 6). These data suggest that catenarin
targets the signaling molecules downstream of CCR5 or
CXCR4. Further, the suppression of MKK6- and MKK7-
mediated chemotaxis by catenarin suggests the possibility
that catenarin targets the signaling molecule(s) upstream
of MKKs (Figure 7). The data shown in Figures 5 and 6
suggest that catenarin acts as a kinase inhibitor. Our data
revealed that catenarin speciﬁcally inhibited the activation of
MKK6/p38 and MKK7/JNK in CXCR4 and CCR5 pathways.
Controversially, catenarin slightly increased the activation
of ERK1/2 in Jurkat cells (Figure 5). The ﬁndings par-
tially correlate with the literature indicating that emodin,
an analog of catenarin, inhibited the phosphorylation of
VEGFR-2 and its downstream eﬀector molecules such as
p38, ERK1/2, FAK, and Akt in endothelial cell line [50,
51]. The discrepancy between the activation of ERK1/2 by
catenarin and the inhibition of ERK1/2 by emodin is due to
the diﬀerence of anthraquinone structure because emodin
did inhibit CXCR4-mediated ERK1/2 activation in Jurkat
cells (data not shown). Most of the literature suggests that
calcium mobilization is located upstream of the activation
of MAPKs [52]; however, some studies have suggested that
MAPKs control intracellular calcium concentration [53].
We found that P38 and JNK inhibitors suppressed calcium
mobilization in CXCR4 and CCR5 pathways (Figure 4),
which argues for the possibility that MAPKs control calcium
mobilization (Figure 7(b)).
In conclusion, we, for the ﬁrst time, showed that
catenarin inhibited CXCR4- and CCR5-implicated leukocyte
migration, islet destruction, and diabetes in NOD mice.
This inhibition involved the inactivation of the MKK6/p38
and MKK7/JNK signaling cascades and the reduction of
calcium inﬂux in the CCR5 and CXCR4 pathways in T cells.
This proof-of-concept study demonstrates the eﬀectiveness
of catenarin against T1D and molecular mechanism of
catenarin in T cells and, probably, other leukocytes.12 Evidence-Based Complementary and Alternative Medicine
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